{
    "nct_id": "NCT05043090",
    "age": "Adults",
    "cancer_center_accrual_goal_upper": 0,
    "curated_on": "2021-09-13",
    "study_start_date": "2021-10-28",
    "study_completion_date": "",
    "data_table4": "Interventional",
    "drug_list": {
        "drug": [
            {
                "drug_name": "Drug: durvalumab"
            },
            {
                "drug_name": "Drug: savolitinib"
            },
            {
                "drug_name": "Drug: sunitinib"
            }
        ]
    },
    "long_title": "A Phase III, Open Label, Randomised, 3-Arm, Multi-Centre Study of Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic Papillary Renal Cell Carcinoma (SAMETA)",
    "last_updated": "2025-05-08",
    "management_group_list": {
        "management_group": [
            {
                "is_primary": "Y",
                "management_group_name": "Group1"
            }
        ]
    },
    "oncology_group_list": {
        "oncology_group": [
            {
                "group_name": "Group1",
                "is_primary": "N"
            }
        ]
    },
    "phase": "PHASE3",
    "principal_investigator": "Toni Choueiri, Bryan Li",
    "principal_investigator_institution": "Dana-Farber Cancer Institute, HKU",
    "program_area_list": {
        "program_area": [
            {
                "is_primary": "Y",
                "program_area_name": "Program1"
            }
        ]
    },
    "protocol_id": 0,
    "protocol_ids": [
        "D5086C00001"
    ],
    "protocol_no": "",
    "protocol_target_accrual": 148,
    "protocol_type": "INTERVENTIONAL",
    "prior_treatment_requirements": [
        "Inclusion Criteria:",
        "* Histologically confirmed unresectable and locally advanced or metastatic PRCC",
        "* PRCC must be centrally confirmed as MET-driven using a sponsor-designated central laboratory validated NGS assay",
        "* No prior systemic anti-cancer treatment in the metastatic setting; no prior exposure to MET inhibitors, Durvalumab or Sunitinib in any setting",
        "* Karnofsky Score \\>70",
        "* At least one lesion, not previously irradiated, that can be accurately measured at baseline",
        "* Adequate organ and bone marrow function",
        "* Life expectancy \u226512weeks at Day 1",
        "Exclude - Exclusion Criteria:",
        "Exclude - * History of liver cirrhosis of any origin and clinical stage; or history of other serious liver disease or chronic disease with relevant liver involvement, with or without normal LFTs",
        "Exclude - * Spinal cord compression or brain metastases, unless asymptomatic and stable on treatment for at least 14 days prior to study intervention",
        "Exclude - * Active or prior cardiac disease (within past 6 months) or clinically significant ECG abnormalities and/or factors/medications that may affect QT and/or QTc intervals",
        "Exclude - * Active infection including HIV, TB, HBV and HCV",
        "Exclude - * Active or prior documented autoimmune or inflammatory disorders",
        "Exclude - * Receipt of live attenuated vaccine within 30 days prior to the first dose of study intervention"
    ],
    "short_title": "Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC",
    "site_list": {
        "site": []
    },
    "sponsor_list": {
        "sponsor": [
            {
                "is_principal_sponsor": "Y",
                "sponsor_name": "AstraZeneca",
                "sponsor_protocol_no": "",
                "sponsor_roles": "sponsor"
            }
        ]
    },
    "staff_list": {
        "protocol_staff": []
    },
    "status": "open to accrual",
    "summary": "A clinical trial to compare the effectiveness of savolitinib plus durvalumab versus sunitinib in MET-driven (hepatocyte growth factor receptor), unresectable and locally advanced or metastatic PRCC (Papillary Renal Cell Carcinoma).",
    "treatment_list": {
        "step": [
            {
                "step_internal_id": 111,
                "step_code": "1",
                "step_type": "Registration",
                "arm": [
                    {
                        "arm_code": "Arm A",
                        "arm_internal_id": 0,
                        "arm_description": "savolitinib 600mg plus durvalumab 1500mg",
                        "arm_suspended": "N",
                        "dose_level": [
                            {
                                "level_code": "0",
                                "level_description": "Drug: savolitinib",
                                "level_internal_id": 0,
                                "level_suspended": "N"
                            },
                            {
                                "level_code": "1",
                                "level_description": "Drug: durvalumab",
                                "level_internal_id": 1,
                                "level_suspended": "N"
                            }
                        ]
                    },
                    {
                        "arm_code": "Arm B",
                        "arm_internal_id": 1,
                        "arm_description": "sunitinib 50mg",
                        "arm_suspended": "N",
                        "dose_level": [
                            {
                                "level_code": "0",
                                "level_description": "Drug: sunitinib",
                                "level_internal_id": 0,
                                "level_suspended": "N"
                            }
                        ]
                    },
                    {
                        "arm_code": "Arm C",
                        "arm_internal_id": 2,
                        "arm_description": "durvalumab 1500mg",
                        "arm_suspended": "N",
                        "dose_level": [
                            {
                                "level_code": "0",
                                "level_description": "Drug: durvalumab",
                                "level_internal_id": 0,
                                "level_suspended": "N"
                            }
                        ]
                    }
                ],
                "match": [
                    {
                        "and": [
                            {
                                "clinical": {
                                    "age_numerical": ">=18",
                                    "disease_status": [
                                        "Locally Advanced",
                                        "Metastatic"
                                    ],
                                    "oncotree_primary_diagnosis": "Renal Cell Carcinoma"
                                }
                            },
                            {
                                "or": [
                                    {
                                        "genomic": {
                                            "hugo_symbol": "MET",
                                            "variant_category": "Mutation"
                                        }
                                    }
                                ]
                            }
                        ]
                    }
                ]
            }
        ]
    }
}